nitric oxide + sildenafil

This therapeutic approach involves the sequential or combined use of inhaled nitric oxide (iNO) and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn (PPHN). Inhaled nitric oxide acts as a potent selective pulmonary vasodilator by stimulating soluble guanylate cyclase to increase cyclic guanosine monophosphate (cGMP) levels. Sildenafil, a selective phosphodiesterase type 5 (PDE5) inhibitor, complements this by preventing the degradation of cGMP. The Third Military Medical University investigated a regimen where iNO is used as the primary treatment for the first 48 hours and then transitioned to oral sildenafil to mitigate the risks associated with long-term NO exposure, such as nitrogen dioxide toxicity and impaired pulmonary surfactant production.

Other names

NO inhalation continued with sildenafilNitric oxide followed by sildenafil